Supplementary Table S4. Treatment exposure by PD-L1 subgroup (PD-L1 safety population)

	Durvalumab + EP (*n* = 152)		**Durvalumab + tremelimumab + EP (*n* = 157)**		**EP (*n* = 127)**	
	TC and IC <1%	**TC or IC ≥1%**	**TC and IC <1%**	**TC or IC ≥1%**	**TC and IC <1%**	**TC or IC ≥1%**
Immunotherapy	**(*n* = 114)**	**(*n* = 38)**	**(*n* = 103)**	**(*n* = 54)**	**(*n* = 95)**	**(*n* = 32)**
Median number of durvalumab doses (range)	7 (1–37)	9 (1–33)	6 (1–32)	7 (1–31)	-	-
Median total duration of durvalumab (range), weeks	26.7 (0.3–136.9)	34.3 (2.7–131.0)	22.3 (2.0–124.9)	28.2 (0.1–125.9)	-	-
Median number of tremelimumab doses (range)	-	-	5 (1–5)	5 (1–6)	-	-
Patients receiving 5 tremelimumab doses, n (%)	-	-	63 (61.2)	41 (75.9)	-	-
Median total duration of tremelimumab (range), weeks	-	-	20.1 (2.0–30.9)	20.0 (0.1–27.3)	-	-
Chemotherapy	**(*n* = 114)**	**(*n* = 38)**	**(*n* = 103)**	**(*n* = 53*)**	**(*n* = 95)**	**(*n* = 32)**
Patients treated with platinum, n (%)†						
Carboplatin	92 (80.7)	31 (81.6)	81 (78.6)	42 (79.2)	78 (82.1)	27 (84.4)
Cisplatin	25 (21.9)	9 (23.7)	25 (24.3)	11 (20.8)	23 (24.2)	6 (18.8)
Median number of cycles of EP (range)‡	4 (1–5)	4 (1–5)	4 (1–4)	4 (1–4)	6 (1–6)	6 (1–6)
Patients receiving ≥4 cycles of EP, n (%)‡	102 (89.5)	34 (89.5)	86 (83.5)	45 (84.9)	78 (82.1)	29 (90.6)
Patients receiving ≥5 cycles of EP, n (%)‡	1 (0.9)	1 (2.6)	0	0	65 (68.4)	23 (71.9)
Patients receiving 6 cycles of EP, n (%)‡	0	0	0	0	61 (64.2)	22 (68.8)
Median total duration of EP (range), weeks‡	12.1 (0.3–18.0)	12.2 (2.7–18.4)	12.3 (2.0–19.0)	12.0 (3.0–17.1)	19.0 (0.4–25.9)	19.0 (1.7–24.1)

*One patient in the durvalumab plus tremelimumab plus EP arm discontinued due to adverse events during the immunotherapy infusions before receiving any EP. †Patients were allowed to switch between carboplatin and cisplatin at the investigator's discretion. ‡Based on etoposide exposure

EP, platinum-etoposide; IC, immune cell; PD-L1, programmed cell death ligand-1; TC, tumor cell.